|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
1997-10-3
|
|
pubmed:abstractText |
Glial cell line-derived neurotrophic factor (GDNF) injected intranigrally protects midbrain dopamine neurons against 6-hydroxydopamine (6-OHDA) toxicity. The timing between GDNF administration and exposure to 6-OHDA is critical in achieving optimal protection. When injected 6 hr before an intranigral injection of 6-OHDA, GDNF provides complete protection as measured by the number of surviving neurons in the substantia nigra of adult rats. The surviving neuronal population decreases by approximately 50% with 12 and 24 hr separating GDNF and 6-OHDA administrations. In controls with 6-OHDA lesions, there is <10% survival of nigral dopamine neurons. No significant increase in survival is seen with either concurrent injections of GDNF and 6-OHDA or 1 hr GDNF pretreatment. Based on HPLC measurements, striatal and midbrain dopamine levels are at least twofold higher on the lesioned side in animals receiving GDNF 6 hr before a 6-OHDA lesion compared with vehicle recipients. Protein synthesis is necessary for GDNF-induced neuroprotective effects because cycloheximide pretreatment that inhibits protein synthesis also blocks neuroprotection.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/3,4-Dihydroxyphenylacetic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Cycloheximide,
http://linkedlifedata.com/resource/pubmed/chemical/Gdnf protein, rat,
http://linkedlifedata.com/resource/pubmed/chemical/Glial Cell Line-Derived...,
http://linkedlifedata.com/resource/pubmed/chemical/Nerve Growth Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Nerve Tissue Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Neuroprotective Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Oxidopamine,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Synthesis Inhibitors
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0270-6474
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7111-8
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:9278545-3,4-Dihydroxyphenylacetic Acid,
pubmed-meshheading:9278545-Animals,
pubmed-meshheading:9278545-Cell Survival,
pubmed-meshheading:9278545-Chromatography, High Pressure Liquid,
pubmed-meshheading:9278545-Cycloheximide,
pubmed-meshheading:9278545-Dopamine,
pubmed-meshheading:9278545-Glial Cell Line-Derived Neurotrophic Factor,
pubmed-meshheading:9278545-Injections, Intraventricular,
pubmed-meshheading:9278545-Male,
pubmed-meshheading:9278545-Nerve Growth Factors,
pubmed-meshheading:9278545-Nerve Tissue Proteins,
pubmed-meshheading:9278545-Neuroprotective Agents,
pubmed-meshheading:9278545-Oxidopamine,
pubmed-meshheading:9278545-Protein Biosynthesis,
pubmed-meshheading:9278545-Protein Synthesis Inhibitors,
pubmed-meshheading:9278545-Rats,
pubmed-meshheading:9278545-Rats, Inbred F344,
pubmed-meshheading:9278545-Substantia Nigra,
pubmed-meshheading:9278545-Ventral Tegmental Area
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis.
|
|
pubmed:affiliation |
Department of Anatomy and Neurobiology, University of Kentucky Medical Center, Lexington, Kentucky 40536, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
